<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01039961</url>
  </required_header>
  <id_info>
    <org_study_id>113022</org_study_id>
    <nct_id>NCT01039961</nct_id>
  </id_info>
  <brief_title>PK Study of IV Formulation of GW856553</brief_title>
  <official_title>Evaluation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Intravenous Dose(s) and a Single Oral Dose of GW856553 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of an IV infusion of GW856553 in healthy&#xD;
      volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aims of this study are to evaluate the safety and tolerability of single intravenous (IV)&#xD;
      doses of GW856553 in healthy adult subjects and to investigate the relationship between PK&#xD;
      and PD markers within the first few hours following administration of study drug to support&#xD;
      progression of this formulation into a patient population.&#xD;
&#xD;
      Subjects in Cohort 1 (n=4) will receive a single 1mg IV dose (given as a 15 minute infusion)&#xD;
      of GW856553. Safety, tolerability and PK exposures will be reviewed, and in an optional&#xD;
      cohort (Cohort 2) (n=4), the dose may be adjusted upward or downward based on data from&#xD;
      Cohort 1. Based on the results from Cohort 1 (and Cohort 2 if required), Cohort 3 (n=12) will&#xD;
      be dosed appropriately to receive a single IV 15 minute infusion of GW856553.&#xD;
&#xD;
      After a one week washout, Cohort 3 subjects will receive a single oral dose of 15mg GW856553.&#xD;
      Access to both IV and oral PK in the same individuals will permit calculation of absolute&#xD;
      bioavailability for the oral dose. Subjects will be resident in the research unit from the&#xD;
      morning prior to dosing until after the last PK blood sample is collected at 24 hours after&#xD;
      the dose of study drug (excluding any washout period).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2, 2010</start_date>
  <completion_date type="Actual">April 15, 2010</completion_date>
  <primary_completion_date type="Actual">April 15, 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>General safety and tolerability endpoints include changes in clinical laboratory assessments, spontaneous AE reporting, ECGs, vital signs and nursing/physician observations.</measure>
    <time_frame>Up to 15 days post IV infusion.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>pHSP27 measurements</measure>
    <time_frame>Up to 24 hours post dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hsCRP measurements</measure>
    <time_frame>Up to 24 hours post dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration [Cmax]</measure>
    <time_frame>Up to 24 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve [AUC]</measure>
    <time_frame>Up to 24 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum plasma concentation [Tmax]</measure>
    <time_frame>Up to 24 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half life [T1/2]</measure>
    <time_frame>Up to 24 hours post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>1 mg IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Unit Dose Strength: 0.4 mg/mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>?mg IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dose to be determined based on PK of first IV dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15 mg (oral)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>two 7.5 mg tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>losmapimod 1 mg</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>1 mg IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>losmapimod</intervention_name>
    <description>IV infusion (dose to be determined based on PK from first dose)</description>
    <arm_group_label>?mg IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>losmapimod 15 mg</intervention_name>
    <description>oral, two 7.5 mg tablets</description>
    <arm_group_label>15 mg (oral)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  AST, ALT, alkaline phosphatase and bilirubin â‰¤ 1.5xULN (isolated bilirubin &gt;1.5xULN is&#xD;
             acceptable if bilirubin is fractionated and direct bilirubin &lt;35%).&#xD;
&#xD;
          -  Healthy as determined by a responsible and experienced physician, based on a medical&#xD;
             evaluation including medical history, physical examination, laboratory tests and&#xD;
             cardiac monitoring.&#xD;
&#xD;
          -  Male or female between 18 and 75 years of age inclusive, at the time of signing the&#xD;
             informed consent.&#xD;
&#xD;
          -  A female subject is eligible to participate if she is of non-childbearing potential&#xD;
             defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or&#xD;
             postmenopausal defined as 12 months of spontaneous amenorrhoea&#xD;
&#xD;
          -  Male subjects must agree to use contraception from the time of the first dose of study&#xD;
             medication until seven days following the last dose.&#xD;
&#xD;
          -  Body weight &gt;50kg (110 pounds) and body mass index (BMI) within the range &gt;19 and&#xD;
             &lt;30kg/m2.&#xD;
&#xD;
          -  Capable of giving written informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the consent form.&#xD;
&#xD;
          -  QTcB or QTcF &lt; 450 msec.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody&#xD;
             result within 3 months of screening&#xD;
&#xD;
          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities&#xD;
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).&#xD;
&#xD;
          -  A positive pre-study drug/alcohol screen.&#xD;
&#xD;
          -  A positive test for HIV antibody.&#xD;
&#xD;
          -  History of regular alcohol consumption within 6 months of the study defined as an&#xD;
             average weekly intake of &gt;21 units for males or &gt;14 units for females. One unit is&#xD;
             equivalent to 8g of alcohol: a half-pint (~240 ml) of beer, 1 glass (125ml) of wine or&#xD;
             1 (25ml) measure of spirits.&#xD;
&#xD;
          -  Treatment with an investigational product within 90 days or 5 half-lives or twice the&#xD;
             duration of the biological effect of the investigational product (whichever is longer)&#xD;
             prior to dosing in this study.&#xD;
&#xD;
          -  Exposure to more than four new chemical entities within 12 months prior to the first&#xD;
             dosing day.&#xD;
&#xD;
          -  Where participation in the study would result in donation of blood or blood products&#xD;
             in excess of 500mL within a 56 day period.&#xD;
&#xD;
          -  Pregnant females as determined by positive serum or urine hCG test at screening or&#xD;
             prior to dosing.&#xD;
&#xD;
          -  Lactating females.&#xD;
&#xD;
          -  Unwillingness or inability to follow the procedures outlined in the protocol.&#xD;
&#xD;
          -  Subject is mentally or legally incapacitated.&#xD;
&#xD;
          -  Taking prescription or non-prescription drugs (including vitamins and dietary or&#xD;
             herbal supplements), within 7 days (or 14 days if the drug is a potential enzyme&#xD;
             inducer) or 5 half-lives (whichever is longer) prior to the first dose of study&#xD;
             medication until completion of the follow-up visit, unless in the opinion of the&#xD;
             Investigator and Sponsor the medication will not interfere with the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 2GG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Barbour AM, Sarov-Blat L, Cai G, Fossler MJ, Sprecher DL, Graggaber J, McGeoch AT, Maison J, Cheriyan J. Safety, tolerability, pharmacokinetics and pharmacodynamics of losmapimod following a single intravenous or oral dose in healthy volunteers. Br J Clin Pharmacol. 2013 Jul;76(1):99-106. doi: 10.1111/bcp.12063.</citation>
    <PMID>23215699</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>December 23, 2009</study_first_submitted>
  <study_first_submitted_qc>December 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2009</study_first_posted>
  <last_update_submitted>June 13, 2017</last_update_submitted>
  <last_update_submitted_qc>June 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>healthy volunteers</keyword>
  <keyword>IV formulation study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>113022</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113022</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113022</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113022</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113022</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113022</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113022</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

